Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

NEW HAVEN, Conn., Jan. 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY

Pfizer

NEW HAVEN, Conn. and NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States

NEW HAVEN, Conn., Dec. 13, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE

Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.

Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its primary endpoints in a Phase 3 trial. The drug, zavegepant, a small-molecule CGRP receptor that can work as a spray and an oral med, showed "ultra-rapid pain relief" at the earliest measured time point of 15 minutes and sustained efficacy through 48 hours after a single intranasal dose in acute migraine.

Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial

NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application

NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer

Biohaven to leverage Artizan's biobanking expertise and proprietary drug discovery engine to create Parkinson's disease drug development program Biohaven to leverage Artizan's biobanking expertise and proprietary drug discovery engine to create Parkinson's disease drug development program

Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson's Disease

NEW HAVEN, Conn., Nov. 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine

NEW HAVEN, Conn., Nov. 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.

Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2021 Results - Earnings Call Transcript

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S. Rimegepant is commercialized as Nurtec ODT in the U.S. and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults.

Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -7.79% and 1.45%, respectively, for the quarter ended September 2021.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q3 Loss, Tops Revenue Estimates

Shares of Biohaven Pharmaceutical Holding Company Ltd. BHVN, -4.29% tumbled 15.2% in premarket trading on Tuesday after it announced a deal worth up to $1.2 billion with Pfizer Inc. PFE, -0.58% to commercialize the company's migraine treatment outside of the U.S. Pfizer's stock was down 0.4% in trading before the market opened on Tuesday.

Biohaven's stock slides 15% on deal with Pfizer for its migraine drug

NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States

NEW HAVEN, Conn., Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments

NEW HAVEN, Conn., Nov. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021

MOORESVILLE, N.C., Nov. 2, 2021 /PRNewswire/ -- Rick Ware Racing (RWR) has joined forces once again with Nine Line Apparel and Biohaven Pharmaceuticals' Nurtec® ODT (rimegepant) to pay tribute and honor the upcoming 80th Anniversary of the Attack on Pearl Harbor this weekend at Phoenix Raceway for the season finale.

Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans Ahead of 80th Anniversary at Phoenix Raceway

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Q3 Earnings?

NEW HAVEN, Conn., Oct. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma

Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.

Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations

NEW HAVEN, Conn., Oct. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment

Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.

Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has announced results from a focused analysis of verdiperstat trial in verdiperstat in multiple system atrophy (MSA).  Verdiperstat did not differ statistically from placebo on the prespecified primary efficacy measure or the key secondary efficacy measures.

News for Biohaven Pharmaceutical Hld Stock (BHVN)